Important note: Information you find here was accurate at the time of publication. The state of the art may have changed since the publication date.

HIV infection is now a chronic disease, with more antiretroviral therapy (ART) being used in more patients for longer periods. However, the long-term management of HIV disease is complex; a fine balance exists between the benefits and adverse events (AEs). AEs associated with ART are common and many have serious clinical manifestations and metabolic alterations that affect a patient’s adherence to therapy

Lipodystrophy, the AE most unique to HIV and ART, remains one of the most complex, multidisciplinary and challenging fields of research and clinical management. Other serious AEs include dyslipidaemia, abnormalities in glucose homeostasis, mitochondrial toxicity and accelerated cardiovascular disease, as well as osteopenia, neurological toxicities, diarrhoea and sexual dysfunction, have also become matters of prime clinical importance. Moreover, as new agents become available and new drug combinations are used patients will experience different AEs.

The International Workshops on Adverse Drug Reactions and Lipodystrophy in HIV address the range of adverse events, with plenary sessions to review issues such as: HIV and the kidney; cardiovascular risk; and toxicity of new agents. We aim to provide a lively discussion forum for treating physicians and researchers to exchange information, whilst increasing our understanding of lipodystrophy and the many and varied AEs associated with ART. The workshop will also be CME accredited, allowing people to advance their professional development.